Saturday, January 19, 2008

Direct-to-Consumer Advertising and Physician Diagnosing.

Sample distribution Change of magnitude.
Initially, 48 drug classes encompassing 121 specifically advertised agents were represented by the CMR data. Nineteen particular agents were advertised for 19 months or more (not necessarily consecutive months). These 19 drugs encompassed 13 NDCD classes. Both the drug taxonomic category variety and the advertised drugs were examined when selecting drug classes for the analyses. The masses NDCD classes and congressman agents (as they were categorized in NAMCS) were excluded: dermatological (Rogaine), antiarthritic (Relafen), estrogens and progestins (Depo-Provera, Estraderm, and Premarin), pharmaceutical aids (Habitrol), contraceptives (Norplant), and topical steroids (Flonase). The aforementioned drugs and NDCD classes were excluded for one or more of the motion reasons: (1) the NDCD grouping was so broad that the relation between mugwump and dependent variables would have been weak, (2) the drug was approved to become a nonprescription functionary during the memorizer period of time, (3) the drug had multiple approved and off-label therapeutic uses and may be associated with various diagnoses, and (4) establishment of the drug required surgical participation. Also, antifungals were excluded because certain drugs in this pedagogy (Diflucan and Sporanox) had been classified as antiprotozoals in the early period of time of the NAMCS.

No comments: